Alotaibi Hend, Alsalhi Abdulaziz, Albinhar Turki, Alshathry Yazeed, Barakeh Maha
Department of Dermatology, College of Medicine, King Saud University, Riyadh.
Department of Dermatology, King Khalid University Hospital, King Saud University, Riyadh.
Dermatol Reports. 2022 Dec 23;15(2):9632. doi: 10.4081/dr.2023.9632. eCollection 2023 Jun 7.
Adverse events following vaccinations have been noted for centuries, but as of recently, discussions concerning these adverse effects have increased due to the COVID-19 pandemic and the consequent delivery of vaccinations. Through presenting new cases of such adverse events and reviewing the literature, we aim to facilitate the recognition of COVID-19 vaccine-induced autoimmune diseases that may occur in the years after the pandemic has been contained. We report on a case of biopsy-proven morphea after the COVID-19 vaccine, in which case the patient developed diffuse skin lesions all over her body. The patient was known to have chronic urticaria and received two doses of the Pfizer-BioNTech COVID-19 vaccines (BioNTech, Fosun Pharma, Pfizer, New York City, USA). The patient started to notice itchy lesions on her arms two months after taking her second dose of the vaccine. This is the first case reported of generalized morphea following COVID-19 vaccination with another autoimmune disease and represents the first case of generalized morphea reported in the Middle East.
疫苗接种后的不良事件已被记录了几个世纪，但直到最近，由于新冠疫情以及随之而来的疫苗接种，关于这些不良反应的讨论有所增加。通过呈现此类不良事件的新病例并回顾文献，我们旨在促进对新冠疫苗接种后可能在疫情得到控制后的几年里出现的自身免疫性疾病的认识。我们报告了一例新冠疫苗接种后经活检证实的硬斑病病例，该病例中患者全身出现弥漫性皮肤病变。已知该患者患有慢性荨麻疹，并接种了两剂辉瑞 - 生物科技新冠疫苗（BioNTech，复星医药，辉瑞，美国纽约市）。患者在接种第二剂疫苗两个月后开始注意到手臂上出现瘙痒性病变。这是首例报告的接种新冠疫苗后出现泛发性硬斑病并伴有另一种自身免疫性疾病的病例，也是中东地区报告的首例泛发性硬斑病病例。
